November 1, 2010
Common Stomach Bacteria May Fight Off Inflammatory Bowel Disease Caused By Salmonella
Helicobacter pylori in the mouse stomach put the brakes on colitis by reducing the immune response in the lower GI tract, U-M study shows
Helicobacter pylori, a common stomach bacterium, reduced the severity of inflammation of the colon caused by Salmonella in mice, according to research from U-M Medical School scientists.More than half the people in the world are infected with H. pylori, although it is very unusual to find it in the United States. But this research shows there may be an inflammation control benefit to hosting the H. pylori infection, says Peter Higgins, M.D., Ph.D., M.Sc., lead author of the study published last week in the journal Inflammatory Bowel Diseases.
"If we have evolved to live with certain bugs, maybe there is a reason," said Higgins, assistant professor of gastroenterology in U-M's Department of Internal Medicine. "This research demonstrates that having H. pylori in your stomach could have beneficial immune effects in other parts of the body."
In the study, mice were infected with H. pylori, allowed to develop immune tolerance for a month, and then infected with Salmonella, which induces the inflammatory bowel disease colitis. The data provided the first evidence that H. pylori infection in the stomach alters the immunological environment of the lower gastrointestinal tract and reduced the severity of Salmonella-induced colitis.
"This was surprising because H. pylori infects the stomach, not the colon. It appears to have a more global effect on the gut immune system," says John Kao, M.D., senior author of this study and assistant professor in U-M's Department of Internal Medicine.
"But it may explain why people in regions with lots of H. pylori infection "” such as Asia and Africa "” get fewer inflammatory bowel diseases, like ulcerative colitis and Crohn's disease."
It also may explain why H. pylori infection is so common, Higgins says. Salmonella was historically a rampant fatal infection that caused the plague of Athens, which led to rise of Sparta. It also likely led to the early death of Alexander the Great. So it would make sense that many humans carry the H. pylori bacteria, if it truly reduces the severity of inflammation caused by Salmonella, Higgins says.
The H. pylori infection is now more commonly found in developing countries or those with poor sanitation, where Salmonella and inflammatory bowel diseases are more common. Most people contract H. pylori in their first seven years of life, most commonly through exposure to feces.
Higgins does not recommend that inflammatory bowel patients should be infected with H. pylori, however. In the U.S., H. pylori infection is treated with antibiotics because it can lead to stomach ulcers or cancer, even though most people don't notice they have it.
"There may be a reason we co-exist with H. pylori. Maybe we should not be so quick to get rid of it in patients who do not have stomach ulcers," Higgins says, adding that this may be especially true in places where Salmonella remains a common threat.
"It would be reasonable for researchers to look at whether H. pylori infection is associated with reduced severity of other gut infections like cholera or Clostridium difficile. Many more studies are needed, however, to see if H. pylori could actually prevent inflammatory bowel disease."
About U-M's Division of Gastroenterology: U-M is one of the largest gastroenterology practices in the country and is a leader in the prevention, diagnosis, and treatment of diseases of the gastrointestinal tract and liver. Our 50-plus physicians are experts in the diagnosis and treatment of all diseases of the gastrointestinal system, from simple to complex, including those of the esophagus, stomach, small intestine, colon, rectum, liver, gallbladder, pancreas and biliary tract.
In addition to being leaders in the clinic, our faculty are also leaders in their respective areas of research, which span such varied interests as the role of peptides in the brain-gut interactions in functional bowel diseases to innovative treatments of viral hepatitis and liver cancer.
On the Net: